Biocon eyes international markets to supply Itolizumab for Covid-19 therapy

While Biocon has received the Drugs Controller General of India’s (DCGI) approval to market its novel biologic drug Itolizumab in India for treatment of patients with moderate to severe Covid-19 complications, its partner Equillium is planning to carry out a clinical trial in the US, which could lead to huge spike in demand for the product. 

While the US has over 3 million cases, it has reported more than 132,000 deaths to date in the country. 

Currently, there are more than 280,000 active cases in India. According to the World Health Organization, 80 per cent cases are mild, 15 per